Scientist Kim Tieu, PhD has received a $6.6 million grant to investigate the environmental factors that may trigger the death of brain cells in Parkinson’s disease, and to develop therapies that prevent their loss. The grant from the National Institute of Environmental Health Sciences (NIEHS) is part of its Revolutionizing Innovative, Visionary…
Oral treatment with Accordion Pill-Carbidopa/Levodopa (AP-CD/LD) lessened the variability of levodopa plasma levels and eased motor fluctuations in people with advanced Parkinson’s, according to results of a Phase 2 trial. The study, “Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson’s disease”…
A new nationwide event series aims to empower people with Parkinson’s (PD) and their caregivers to manage the disease, learn about research participation, and plug into local resources. Called “Parkinson’s IQ + You,” the effort is presented by The Michael J. Fox Foundation (MJFF). The events seek…
Blocking an enzyme that converts compounds derived from certain foods and tobacco in the brain may become a therapeutic target for people with Parkinson’s, according to a new study of mice. The research, “Mitochondria-targeted cytochrome P450 CYP2D6 is involved in monomethylamine-induced neuronal damage in mouse models,”…
Enterin Inc has enrolled the first patient in its Phase 1b DEMET clinical trial investigating the effectiveness, safety and tolerability of small molecule ENT-01 to treat Parkinson’s disease dementia. Contacts and locations of participating sites can be found here. Many neurodegenerative disorders involve aggregation of misfolded (harmful)…
VistaGen Therapeutics’ candidate, AV-101, reduced levodopa-induced dyskinesia (abnormal involuntary movements) while maintaining levodopa activity in a non-human primate model of Parkinson’s disease. Importantly, AV-101 treatment did not cause the adverse side effects observed with amantadine, a therapy that works similar to AV-101 to ease Parkinson’s symptoms.
Treatment with Copaxone (glatiramer acetate), an FDA-approved medicine for multiple sclerosis, can restore motor function and biochemical markers in a mouse model of Parkinson’s disease, according to a recent study. The findings, “Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in 9 Tyrosine Hydroxylase Levels…
Changes to the serotonin system in the brain occur years before the development of motor symptoms in Parkinson’s — and may be an important early warning signal for the disease, a study suggests. “Therefore, brain imaging of the serotonin system could become a valuable tool to detect individuals at…
Analysis of a natural motor event called “mirror activity” has revealed that the long contraction of muscles in one hand can cause frequent involuntary reactions from the muscles in the opposite hand. These findings provide detailed evidence on how brain-body connectivity works and regulates muscle behavior, which may help identify…
The Accordion Pill Carbidopa/Levodopa (AP-CD/LD) administered three times a day reduced the variability of blood plasma levels of levodopa in Parkinson’s disease patients, which suggests that the treatment may help to ease motor fluctuations, a Phase 2 trial shows. Warren Olanow, MD, professor at Mount Sinai School of Medicine,…
Get regular updates to your inbox.
